ZUPREME trial: Petrelintide results, Phase 3, and current status.
Also searched as ZP8396 · long-acting amylin analogue
Petrelintide is Zealand Pharma and Roche’s investigational once-weekly amylin analogue for chronic weight management. Its Phase 2 story combines double-digit mean loss with a detailed tolerability record, while Phase 3 initiation is planned for the second half of 2026 rather than already confirmed by a recruiting pivotal-trial record.
Is petrelintide already in Phase 3 or available to buy?
Zealand Pharma and Roche have formally endorsed advancing petrelintide to Phase 3 and say chronic-weight-management trials are planned to start in the second half of 2026. At this evidence check, that is a planned milestone rather than a published Phase 3 outcome. Petrelintide is not FDA approved and has no legitimate commercial label, prescription price, or retail pharmacy channel. A product sold online under an investigational name should not be treated as the clinical-trial material studied by the sponsors.
Compare Petrelintide with Retatrutide, without losing the country context.
Put evidence status, ClinicalTrials.gov coverage, official United States records, and qualified US research prices in one view. Blank fields stay blank when the underlying dataset does not support a number.
Investigational clinical program
Official product and seller records attached
Investigational clinical program
What can you conclude about Petrelintide today?
These are dated program facts, not a cross-trial ranking, approval forecast, personal treatment recommendation, or proof that a same-name online product is the sponsor's medicine.
A long-acting investigational analogue designed for once-weekly subcutaneous administration.
Estimated mean loss under the efficacy estimand versus 1.7% with pooled placebo in Phase 2.
ADA poster rate for pooled petrelintide versus pooled placebo; dose-specific rates varied.
Zealand and Roche formally endorsed advancement; initiation timing remains a forward plan until trial records confirm it.
Know which molecule the result belongs to.
- Sponsor
- Zealand Pharma + Roche
- Mechanism
- Long-acting amylin analogue
- Route being studied
- Once-weekly subcutaneous injection
- Current stage
- Phase 3 planned; Phase 2 program active
- Featured trial anchors
- NCT06662539 · NCT06926842 · NCT07589686
- Evidence checked
- July 17, 2026
Petrelintide weight-loss results, with the trial attached.
This visual shows one selected result, not every dose or endpoint in the program. The percentage remains attached to its duration, population, comparator, analysis method, and source.
Evidence checked July 21, 2026Petrelintide reported 10.7% mean reduction at 42 weeks under the efficacy estimand, upper end of five dose-group estimates. The comparator recorded 1.7% mean reduction.
Bar lengths share a 0 to 30% visual scale. They describe this selected record and do not make separate trials head-to-head.
- Population
- Adults with obesity or overweight and weight-related complications
- Participants
- 493 Total randomized trial population
- Dose
- Upper reported dose-group result
- Primary analysis
- Efficacy estimand, upper end of five dose-group estimates
- Regulatory status
- Investigational; not FDA approved
Petrelintide clinical trials by status, phase, and location.
The current exact-intervention snapshot matches 9 unique NCT records. This chart describes registry coverage and current study fields. It does not compare efficacy, safety, approval probability, eligibility, or treatment access.
Snapshot 2026-07-24Counts use individual locations currently marked Recruiting, not every facility listed on an overall-recruiting study. Repeated centers across studies remain repeated site observations.
Petrelintide across 42 countries.
This profile establishes the program identity and its cited clinical or regulatory record. It does not turn a same-name seller listing into the sponsor’s asset or prove authorization, availability, or lawful supply in another destination.
Compare Petrelintide by country →Compare Petrelintide by US state →Browse the global peptide country dataset →Is Petrelintide approved or available in your country?
Start with the United States FDA record, then check the destination that matters to you. Each country page separates drug identity, authorization, product records, seller claims, and supply rules. Directory checked July 20, 2026.
What the record shows - and what it doesn’t.
Trial percentages are kept beside the design details that make them interpretable. Unknowns stay visible instead of being filled with launch speculation.
ZUPREME-1 was a 42-week dose-finding trial
The randomized Phase 2 study enrolled adults with obesity or overweight without type 2 diabetes. Zealand’s ADA materials report estimated mean losses from 8.7% to 10.7% across five petrelintide groups at week 42 under the efficacy estimand, compared with 1.7% for pooled placebo.
The tolerability record needs exact rates
In the ADA presentation, pooled nausea occurred in 19.6% of petrelintide participants versus 6.2% with placebo, diarrhea in 7.4% versus 7.4%, constipation in 6.9% versus 3.7%, and vomiting in 3.0% versus 6.2%. The sponsor’s ‘placebo-like’ summary should be read beside those event-specific data and the five dose groups.
Development extends beyond one population
ZUPREME-2 is a separate 28-week Phase 2 trial in adults with overweight or obesity and type 2 diabetes, with an active, not recruiting record at this check. Zealand and Roche also announced plans to begin Phase 3 chronic-weight-management trials in the second half of 2026.
Phase 3 outcomes do not exist yet
A sponsor decision to advance and a pipeline label are not Phase 3 efficacy or safety results. Pivotal designs, enrolled populations, doses, estimands, completion dates, and outcomes must be read from future trial records and results rather than projected from Phase 2.
No approved commercial product
Petrelintide has no FDA-approved indication, label, retail price, pharmacy channel, or coverage policy. The once-weekly schedule is the schedule under study, not a consumer dosing instruction or evidence that online products bearing the name are authentic.
Durability and comparative position are unresolved
ZUPREME-1 does not establish what happens after long-term discontinuation or whether petrelintide is more tolerable, more effective, or more sustainable than an approved GLP-1 medicine. Those questions require suitably designed longer and comparative trials.
The questions behind the search.
Concise answers based on the dated sponsor and trial records below. This is educational reporting, not medical advice.
What is petrelintide and how is it different from a GLP-1 drug?
Petrelintide, formerly ZP8396, is an investigational long-acting analogue of amylin, a hormone co-secreted with insulin after nutrients are consumed and involved in satiety signaling. It is being studied as a once-weekly injection. It does not use the same primary receptor mechanism as a GLP-1 receptor agonist, although both classes are being investigated for weight management. That mechanistic difference is scientifically useful; it does not by itself prove superior efficacy, tolerability, muscle preservation, or long-term persistence.
What did the ZUPREME-1 petrelintide trial show?
In the sponsor’s ADA 2026 materials, five petrelintide dose groups had estimated mean weight reductions of 8.7% to 10.7% at week 42 under the efficacy estimand, compared with 1.7% for pooled placebo. The trial included 485 participants in the presented analysis, without type 2 diabetes, and used dose escalation followed by maintenance. Pooled nausea was 19.6% with petrelintide versus 6.2% with placebo, while several other gastrointestinal event rates were closer. Those details are more informative than a single ‘placebo-like’ slogan.
Is petrelintide already in Phase 3 or available to buy?
Zealand Pharma and Roche have formally endorsed advancing petrelintide to Phase 3 and say chronic-weight-management trials are planned to start in the second half of 2026. At this evidence check, that is a planned milestone rather than a published Phase 3 outcome. Petrelintide is not FDA approved and has no legitimate commercial label, prescription price, or retail pharmacy channel. A product sold online under an investigational name should not be treated as the clinical-trial material studied by the sponsors.
Do not use an investigational name, trial dose, or online research listing as a substitute for approved care. This page does not recommend treatment, sourcing, or participation in a clinical trial.
Understand the product-category boundary →